Summit Stock Jumps 17% on $2 Billion AstraZeneca Investment

Summit Therapeutics NASDAQ:SMMT, which holds rights to the cancer drug ivonescimab in major markets outside China, rose 16.99% in premarket after AstraZeneca NYSE:AZN agreed to invest $2 billion in newly issued Summit equity. AstraZeneca shares rose 1.22% in London trading.AstraZeneca will buy abou…